Nutra Pharma Corporation (OTC: NPHC), Liquidmetal Technologies, Inc. (OTC: LQMT) and GTx, Inc., (NASDAQ: GTXI) are our New Small Cap Stock Reports today.
Nutra Pharma Corporation (OTC: NPHC) operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin(R) and Nyloxin(TM)
On October 22 NPHC announced that their Chief Executive Officer, Rik J Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is an update to the previous one posted in August and provides an outline for the short, mid-term and long-term goals of the company. Castaldo also updated his interview with Jonathan Flicker, the CEO of Nutra Pharma's Nyloxin(R) Distributor, New Vitalit
For our complete article on NPHC please go here: http://tinyurl.com/otcmagic-nphc
Liquidmetal Technologies, Inc. (OTC: LQMT) is the leading developer of bulk alloys and composites that utilize the performance advantages offered by amorphous alloy technology. Amorphous alloys are unique materials that are distinguished by their ability to retain a random structure when they solidify, in contrast to the crystalline atomic structure that forms in ordinary metals and alloys. Liquidmetal Technologies is the first company to produce amorphous alloys in commercially viable bulk form, enabling significant improvements in products across a wide array of industries.
For our complete article on LQMT please go here: http://tinyurl.com/otcmagic-liquid
GTx, Inc., (NASDAQ: GTXI) headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.
On October 24 GTXI announced Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer. Enobosarm had a significant effect on Lean Body Mass (LBM) and stair climb power (SCP) through Day 84 and 147 in POWER1 trial (platinum plus taxane) using a longitudinal continuous variable analysis
OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.
Subscribe Here: http://www.otcmagic.com/
Contact Info:
OTCMagic
[email protected]